In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $13.89 down -3.00% from its previous closing price of $14.32. In other words, the price has decreased by -$3.00 from its previous closing price. On the day, 1.31 million shares were traded. AMLX stock price reached its highest trading level at $14.365 during the session, while it also had its lowest trading level at $13.77.
Ratios:
For a deeper understanding of Amylyx Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.72 and its Current Ratio is at 8.72. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 30 ’25 when Klee Justin B. sold 29,975 shares for $14.38 per share. The transaction valued at 430,952 led to the insider holds 3,325,301 shares of the business.
Mazzariello Gina sold 8,828 shares of AMLX for $128,669 on Sep 30 ’25. The Chief Legal Officer now owns 148,141 shares after completing the transaction at $14.58 per share. On Sep 30 ’25, another insider, FRATES JAMES M, who serves as the Chief Financial Officer of the company, sold 10,558 shares for $14.65 each. As a result, the insider received 154,650 and left with 280,430 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1481610624 and an Enterprise Value of 1063671616. Its current Enterprise Value per Revenue stands at -4271.774 whereas that against EBITDA is -5.419.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.33, which has changed by 1.5722222 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $16.96, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of the stock is 10.54%, while the 200-Day Moving Average is calculated to be 99.73%.
Shares Statistics:
For the past three months, AMLX has traded an average of 1.69M shares per day and 1621410 over the past ten days. A total of 106.67M shares are outstanding, with a floating share count of 90.01M. Insiders hold about 15.62% of the company’s shares, while institutions hold 70.82% stake in the company. Shares short for AMLX as of 1760486400 were 9616175 with a Short Ratio of 5.70, compared to 1757894400 on 8774952. Therefore, it implies a Short% of Shares Outstanding of 9616175 and a Short% of Float of 9.7799994.
Earnings Estimates
. The current rating of Amylyx Pharmaceuticals Inc (AMLX) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.06 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$1.17 and -$1.9 for the fiscal current year, implying an average EPS of -$1.61. EPS for the following year is -$1.3, with 7.0 analysts recommending between -$0.76 and -$2.05.
